Catherine Bingham

Catherine Bingham General Information

Biography

Ms. Catherine Bingham serves as Managing Partner at SV Health Investors. She serves as Chairman at Alchemab Therapeutics. She co-leads SV's biotech franchise which has a long history of building high-value, successful new companies developing transformational new medicines and bringing drugs from discovery to market. She serves as a board member of Alchemab and Pulmocide. Her investments, many of which are examples of SV's company creation approach to biotech investing, include a wide range of drug discovery and development companies focused on different clinical areas in companies in the UK, EU, and US. In 2021 she was awarded a DBE in the Queen's Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of world-class experts with the shared purpose of finding and manufacturing COVID-19 vaccines. She serves as a Board Member at Enara Bio. Previously, She served as a Board Member at Trex Bio. She holds a first-class degree in biochemistry, from the University of Oxford; and an MBA, from Harvard Business School (Baker Scholar).